Deciding whether SVF-enriched grafting is worth it over conventional grafting
ما هي الحالة
Clinic marketing often calls cell-enriched grafting "stem cell fat grafting". A person deciding between it and conventional grafting needs to know what is actually added (stromal vascular fraction), what pooled studies say about retention, how strong that evidence is, the regulatory position in Korea and the United States, and the extra cost. The situation is an evidence-reading task, so study quality and contrary findings belong in the answer.
مخاوف شائعة: distrust of marketing · fear of paying for hype · hope for better survival
ما يوازنه الناس في هذه الحالة
يُجاب عن كل شرط بحقائق من صفحات الكيانات؛ وتقود علامات [n] إلى المصدر.
What is added to the graft
- Original procedure
- About half of the aspirated fat is processed to isolate fresh SVF, which is recombined with the other half before injection; the fat acts as a living scaffold[3]journalCell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells, Yoshimura K et al.Aesthetic Plastic Surgery
- Also called
- Cell-assisted lipotransfer (CAL)[1]academicCell-Assisted Lipotransfer: A Systematic Review of its EfficacyAesthetic Plastic Surgery (2024)
- Proposed mechanism
- Stromal cells may support angiogenesis and graft survival (hypothesis under study)[2]academicAdvancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategiesFrontiers in Cell and Developmental Biology (2026)
Retention difference in pooled studies
- Pooled fat survival (2026 meta-analysis)
- 72.78% with enrichment vs 45.28% conventional (SMD 2.44; 95% CI 1.00–3.88); 15 studies, 634 patients; heterogeneity I² = 97.19%[4]journalClinical Efficacy of Adipose-Derived Stem Cell-Enriched Lipotransfer Versus Conventional Fat Grafting: A Systematic Review and Meta-AnalysisCureus, via PubMed Central
- Efficacy by site
- Face showed a significant benefit (SMD 2.95); breast reconstruction showed no significant advantage (SMD 0.47); no benefit with water-assisted lipotransfer harvesting[4]journalClinical Efficacy of Adipose-Derived Stem Cell-Enriched Lipotransfer Versus Conventional Fat Grafting: A Systematic Review and Meta-AnalysisCureus, via PubMed Central
Strength of the evidence
- Methodological quality
- About 62% of included studies rated weak overall; mean follow-up 16.2 months, too short for oncologic conclusions[4]journalClinical Efficacy of Adipose-Derived Stem Cell-Enriched Lipotransfer Versus Conventional Fat Grafting: A Systematic Review and Meta-AnalysisCureus, via PubMed Central
- Comparative study without benefit
- Peltoniemi et al. 2013 (JPRAS 66:1494–1503): 18 women, MRI at 6 months; graft survival 50% with Celution SVF enrichment vs 54% without, difference not significant[5]journalStem cell enrichment does not warrant a higher graft survival in lipofilling of the breast: a prospective comparative studyJournal of Plastic, Reconstructive & Aesthetic Surgery (record via Europe PMC)
- Breast-surgery evidence base
- 11 studies, 336 patients, follow-up 6–42 months; 8 of 11 studies had no control group; only one used a validated patient-reported outcome measure (BREAST-Q)[6]journalCell assisted lipotransfer in breast augmentation and reconstruction: A systematic review of safety, efficacy, use of patient reported outcomes and study qualityJPRAS Open via PubMed Central
Regulatory status
- Applicable US FDA guidance
- Final guidance 'Regulatory Considerations for HCT/Ps: Minimal Manipulation and Homologous Use', July 2020 (supersedes November 2017 version)[7]governmentRegulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous UseU.S. Food and Drug Administration
- Enzymatic SVF isolation (US)
- Collagenase digestion to isolate SVF falls outside 'minimal manipulation'; non-enzymatic mechanical point-of-care methods are proposed as possible alternatives[8]journalIntraoperative Strategies for Minimal Manipulation of Autologous Adipose Tissue for Cell- and Tissue-Based Therapies: Concise Review (Trivisonno A et al.)Stem Cells Translational Medicine / PubMed Central
Korean regulatory status
- Korea: Advanced Regenerative Bio Act amendmentSVF Breast Augmentation
- Effective 2025-02-21: regenerative-medicine treatment allowed only for serious, rare or intractable diseases, at designated institutions, with review-committee approval of treatment plans[10]government첨단재생의료에 대한 환자 접근성은 향상되고, 안전관리는 강화됩니다보건복지부
أسئلة ذات صلة
كيفية التحقق من مؤسسة
بدلاً من الترتيب، استخدم السجلات العامة الموجودة في كوريا لهذا النوع من الإجراءات.
- تحقق من رقم التعيين في قائمة وزارة الصحة والرعاية للمؤسسات المعيّنة للطب التجديدي المتقدم.
- عند عزل الخلايا أو معالجتها، تحقق من سجل تراخيص منشآت معالجة الخلايا (K-ARM).
- اعتبر أعداد الحالات ومعدلات النجاح وعبارات "الأول" التي تنشرها المؤسسة عن نفسها ادعاءات رسمية حتى يؤكدها سجل مستقل.
مؤسسات هذا المجال التي ذكرتها جهة تنظيمية مستقلة أو سجل أو منشور محكّم، مرتبة أبجدياً. الإدراج سجل وليس توصية.
- SC301의원 · Seoulمذكور من جهة رسمية 3
المراجع
- المستوى B · academicCell-Assisted Lipotransfer: A Systematic Review of its Efficacy — Aesthetic Plastic Surgery (2024) · صفحة الدليل
- المستوى B · academicAdvancing fat graft survival: from adipose-derived stem cell mechanisms to next-generation regenerative strategies — Frontiers in Cell and Developmental Biology (2026) · صفحة الدليل
- المستوى B · journalCell-Assisted Lipotransfer for Cosmetic Breast Augmentation: Supportive Use of Adipose-Derived Stem/Stromal Cells, Yoshimura K et al. — Aesthetic Plastic Surgery · صفحة الدليل
- المستوى B · journalClinical Efficacy of Adipose-Derived Stem Cell-Enriched Lipotransfer Versus Conventional Fat Grafting: A Systematic Review and Meta-Analysis — Cureus, via PubMed Central · صفحة الدليل
- المستوى B · journalStem cell enrichment does not warrant a higher graft survival in lipofilling of the breast: a prospective comparative study — Journal of Plastic, Reconstructive & Aesthetic Surgery (record via Europe PMC) · صفحة الدليل
- المستوى B · journalCell assisted lipotransfer in breast augmentation and reconstruction: A systematic review of safety, efficacy, use of patient reported outcomes and study quality — JPRAS Open via PubMed Central · صفحة الدليل
- المستوى A · governmentRegulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use — U.S. Food and Drug Administration · صفحة الدليل
- المستوى B · journalIntraoperative Strategies for Minimal Manipulation of Autologous Adipose Tissue for Cell- and Tissue-Based Therapies: Concise Review (Trivisonno A et al.) — Stem Cells Translational Medicine / PubMed Central · صفحة الدليل
- المستوى A · governmentWarning Letter: US Stem Cell Clinic, LLC (524470) — U.S. Food and Drug Administration · صفحة الدليل
- المستوى A · government첨단재생의료에 대한 환자 접근성은 향상되고, 안전관리는 강화됩니다 — 보건복지부 · صفحة الدليل